[go: up one dir, main page]

PL1889067T3 - Aneksyna do oceny ryzyka wystąpienia raka - Google Patents

Aneksyna do oceny ryzyka wystąpienia raka

Info

Publication number
PL1889067T3
PL1889067T3 PL06743012T PL06743012T PL1889067T3 PL 1889067 T3 PL1889067 T3 PL 1889067T3 PL 06743012 T PL06743012 T PL 06743012T PL 06743012 T PL06743012 T PL 06743012T PL 1889067 T3 PL1889067 T3 PL 1889067T3
Authority
PL
Poland
Prior art keywords
annexin
risk assessment
cancer risk
tissue
urogenital
Prior art date
Application number
PL06743012T
Other languages
English (en)
Inventor
Michael Cahill
André Schrattenholz
Original Assignee
Proteosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05011042A external-priority patent/EP1724585A1/en
Application filed by Proteosys Ag filed Critical Proteosys Ag
Publication of PL1889067T3 publication Critical patent/PL1889067T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4718—Lipocortins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06743012T 2005-05-21 2006-05-22 Aneksyna do oceny ryzyka wystąpienia raka PL1889067T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05011042A EP1724585A1 (en) 2005-05-21 2005-05-21 Annexin for cancer risk assessment
EP05026092A EP1724586A3 (en) 2005-05-21 2005-11-30 Annexin for cancer risk assessment
PCT/EP2006/004818 WO2006125580A1 (en) 2005-05-21 2006-05-22 Annexin for cancer risk assessment
EP06743012A EP1889067B1 (en) 2005-05-21 2006-05-22 Annexin for cancer risk assessment

Publications (1)

Publication Number Publication Date
PL1889067T3 true PL1889067T3 (pl) 2011-10-31

Family

ID=36940167

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06743012T PL1889067T3 (pl) 2005-05-21 2006-05-22 Aneksyna do oceny ryzyka wystąpienia raka

Country Status (9)

Country Link
US (1) US8409812B2 (pl)
EP (2) EP1724586A3 (pl)
JP (1) JP2008545634A (pl)
KR (1) KR20080016809A (pl)
AT (1) ATE511653T1 (pl)
AU (1) AU2006251380B2 (pl)
CA (1) CA2608306A1 (pl)
PL (1) PL1889067T3 (pl)
WO (1) WO2006125580A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2024748T3 (da) 2006-06-09 2013-03-18 Proteosys Ag Monoklonale anti-annexin A3-antistoffer til påvisning af prostatacarcinomer
JP2008202978A (ja) * 2007-02-16 2008-09-04 Hirosaki Univ 前立腺癌の診断方法
BRPI0810176A2 (pt) * 2007-04-12 2014-12-30 Proteosys Ag Regulação autoimune de câncer de próstata ppor anexina a3
FR2919062B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'aminoacylase 1 pour le diagnostic in vitro du cancer colorectal.
FR2919064B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine all pour le diagnostic in vitro du cancer colorectal
FR2919061B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal.
FR2919065B1 (fr) 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
FR2919063B1 (fr) * 2007-07-19 2009-10-02 Biomerieux Sa Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal.
FR2919060B1 (fr) * 2007-07-19 2012-11-30 Biomerieux Sa Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal.
AU2008285557B2 (en) 2007-07-19 2014-07-03 Biomerieux Method for the assay of liver fatty acid-binding protein, ACE and CA19-9 for the in vitro diagnosis of colorectal cancer
FR2933773B1 (fr) * 2008-07-10 2013-02-15 Biomerieux Sa Procede de dosage de la proteine disulfide isomerase pour le diagnostic in vitro du cancer colorectal
GB0822836D0 (en) * 2008-12-15 2009-01-21 Oxford Biomedica Ltd Method
EP2395357B1 (en) 2009-02-04 2015-05-06 Tokyo Institute of Technology Method for analyzing PSA, and method for distinguishing between prostate cancer and prostatomegaly employing the analysis method
JP5630757B2 (ja) 2009-10-30 2014-11-26 国立大学法人東京工業大学 Ｐｓａの分析方法、及び前記分析方法を用いた前立腺癌と前立腺肥大症との鑑別方法
FR2968767B1 (fr) 2010-12-08 2012-12-21 Biomerieux Sa Procede et coffret pour le diagnostic in vitro du cancer de la prostate
WO2013076222A1 (en) 2011-11-23 2013-05-30 Proteosys Ag Differential annexin a3 measurements of serum and blood derivatives or fractions thereof for the diagnosis of prostate cancer
WO2013081554A1 (en) * 2011-11-30 2013-06-06 Agency For Science, Technology And Research Gm1 ganglioside to annexin v microparticle polypeptide ratio for biological monitoring
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
FR2991777B1 (fr) 2012-06-07 2015-08-21 Biomerieux Sa Procede de detection et/ou de dosage de l'annexine a3 d'un mammifere dans le sang ou au moins un de ses derives
EP3550306B1 (en) 2014-08-26 2021-03-03 Keio University Anti-cancer agent sensitivity-determining marker
JP7285215B2 (ja) * 2017-06-30 2023-06-01 国立研究開発法人医薬基盤・健康・栄養研究所 大腸がんを検出するためのバイオマーカー
CN117018185A (zh) * 2022-03-18 2023-11-10 江苏靶标生物医药研究所有限公司 TNF-α纳米抗体与PGE2联用在制备溃疡性结肠炎药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511829B1 (en) * 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
US6645465B2 (en) * 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US20020110832A1 (en) 2000-08-03 2002-08-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20040033502A1 (en) * 2001-03-28 2004-02-19 Amanda Williams Gene expression profiles in esophageal tissue
PL363009A1 (pl) * 2001-04-03 2004-11-15 Merck Patent Gmbh Markery nowotworowe raka nerki
US6843980B2 (en) 2001-04-03 2005-01-18 Theseus Imaging, Corp. Methods for using annexin for detecting cell death in vivo and treating associated conditions
AU2002337657A1 (en) * 2001-07-25 2003-02-17 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
AU2002361908A1 (en) 2001-12-31 2003-07-24 Quark Biotech, Inc. Methods for identifying marker genes for cancer
EP1466016A2 (en) * 2002-01-09 2004-10-13 Riken Institute Of Physical And Chemical Research Cancer profiles
DE10302422A1 (de) * 2003-01-21 2004-07-29 Responsif Gmbh Medikament und Verwendung zur Tumortherapie
EP2295976A1 (en) * 2003-03-08 2011-03-16 Auvation Ltd Markers for colorectal cancer
AU2005212829B2 (en) 2004-02-16 2010-09-09 Proteosys Ag Diagnostic marker for cancer
EP1724585A1 (en) * 2005-05-21 2006-11-22 ProteoSys AG Annexin for cancer risk assessment
DK2024748T3 (da) * 2006-06-09 2013-03-18 Proteosys Ag Monoklonale anti-annexin A3-antistoffer til påvisning af prostatacarcinomer

Also Published As

Publication number Publication date
KR20080016809A (ko) 2008-02-22
EP1889067A1 (en) 2008-02-20
EP1889067B1 (en) 2011-06-01
CA2608306A1 (en) 2006-11-30
US20100267051A1 (en) 2010-10-21
AU2006251380A1 (en) 2006-11-30
HK1118095A1 (en) 2009-01-30
ATE511653T1 (de) 2011-06-15
WO2006125580A1 (en) 2006-11-30
JP2008545634A (ja) 2008-12-18
US8409812B2 (en) 2013-04-02
EP1724586A2 (en) 2006-11-22
AU2006251380B2 (en) 2011-05-19
EP1724586A3 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
PL1889067T3 (pl) Aneksyna do oceny ryzyka wystąpienia raka
WO2007041245A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2010056351A3 (en) Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
EP1842065A4 (en) METHODS OF DIAGNOSIS AND PROGNOSIS OF EPITHELIAL CANCERS
WO2009055820A3 (en) Salivary protein biomarkers for human oral cancer
WO2005114190A3 (en) Methods of identifying biomarkers
WO2008070663A3 (en) Companion diagnostic assays for cancer therapy
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2010025414A3 (en) Diagnostics and treatments for vegf-independent tumors
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2010059242A3 (en) Neurodegenerative disease diagnostic compositions and methods of use
WO2006133325A3 (en) Analysis of tissue samples surrounding malignancies
WO2006128042A3 (en) Methods of identifying mutations in nucleic acid
WO2007032876A3 (en) Biomarkers associated with age-related macular degeneration
WO2008103202A3 (en) Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications
WO2006095086A3 (fr) Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
WO2004045376A3 (en) Screening methods to identify treatments for autoimmune disease
WO2006138219A3 (en) Methods of diagnosis / prognosis of inflammatory conditions
WO2003069553A3 (en) Method of image analysis
WO2002057786A3 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
WO2009151693A3 (en) Imaging mass spectrometry for improved prostate cancer diagnostics
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2004063701A3 (en) Methods of diagnosing and treating cancer
WO2008024495A3 (en) Biomarkers associated with age-related macular degeneration